Treatable traits in the NOVELTY study

for the NOVELTY Study Investigators

doi:10.1111/resp.14325

Treatable traits in the NOVELTY study

for the NOVELTY Study Investigators

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Background and objective: Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent and complex diseases that require personalized management. Although a strategy based on treatable traits (TTs) has been proposed, the prevalence and relationship of TTs to the diagnostic label and disease severity established by the attending physician in a real-world setting are unknown. We assessed how the presence/absence of specific TTs relate to the diagnosis and severity of ‘asthma’, ‘COPD’ or ‘asthma + COPD’. Methods: The authors selected 30 frequently occurring TTs from the NOVELTY study cohort (NOVEL observational longiTudinal studY; NCT02760329), a large (n = 11,226), global study that systematically collects data in a real-world setting, both in primary care clinics and specialized centres, for patients with ‘asthma’ (n = 5932, 52.8%), ‘COPD’ (n = 3898, 34.7%) or both (‘asthma + COPD’; n = 1396, 12.4%). Results: The results indicate that (1) the prevalence of the 30 TTs evaluated varied widely, with a mean ± SD of 4.6 ± 2.6, 5.4 ± 2.6 and 6.4 ± 2.8 TTs/patient in those with ‘asthma’, ‘COPD’ and ‘asthma + COPD’, respectively (p < 0.0001); (2) there were no large global geographical variations, but the prevalence of TTs was different in primary versus specialized clinics; (3) several TTs were specific to the diagnosis and severity of disease, but many were not; and (4) both the presence and absence of TTs formed a pattern that is recognized by clinicians to establish a diagnosis and grade its severity. Conclusion: These results provide the largest and most granular characterization of TTs in patients with airway diseases in a real-world setting to date.

Original language	English
Pages (from-to)	929-940
Number of pages	12
Journal	Respirology
Volume	27
Issue number	11
DOIs	https://doi.org/10.1111/resp.14325
State	Published - Nov 2022

Bibliographical note

Funding Information:
The authors thank participants in the NOVELTY study for their willingness to contribute to medical research, and all field investigators for the quality of their work. Editorial support, under the direction of the authors, was provided by Richard Knight, PhD, CMC Connect, McCann Health Medical Communications, and was funded by AstraZeneca, Cambridge, UK, in accordance with Good Publication Practice (GPP3) guidelines. The NOVELTY study is funded by AstraZeneca.

Funding Information:
Alvar Agustí has received payments in his role as a member of the scientific committee of NOVELTY; received research grants from AstraZeneca, Chiesi, GSK, Menarini, MSD and Zambon; consulting fees from AstraZeneca, Chiesi, GSK, Menarini, MSD and Zambon; and payment or honoraria from AstraZeneca, Chiesi, GSK, Menarini, MSD and Zambon. Eleni Rapsomaniki and Rod Hughes are employees of AstraZeneca. Hana Müllerová is an employee and shareholder of AstraZeneca. Richard Beasley received research grants from AstraZeneca, Cure Kids (NZ), Genentech, GSK and HRC (NZ); consulting fees from AstraZeneca, Avillion and Theravance; payment or honoraria from AstraZeneca, Cipla and Asthma and Respiratory Foundation NZ; support for attending meetings from AstraZeneca and Theravance; and is the Chair of the adult asthma guidelines group for the Asthma and Respiratory Foundation of NZ. Alberto Papi received research grants from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Pfizer, Sanofi and Teva; consulting fees from AstraZeneca, Avillion, Chiesi, Elpen Pharmaceuticals, GSK, IQVIA, Novartis and Sanofi; and payment or honoraria from AstraZeneca, Avillion, Boehringer Ingelheim, Chiesi, Edmond Pharma, Elpen Pharmaceuticals, GSK, IQVIA, Menarini, MSD, Mundipharma, Novartis, Sanofi, Teva and Zambon. Ian D. Pavord received research grants from Chiesi; consulting fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Dey Pharma, Genentech, GSK, Knopp Biosciences, Merck, MSD, Napp Pharmaceuticals, Novartis, Regeneron Pharmaceuticals Inc., Respivert, Schering‐Plough and Teva; payment or honoraria from Aerocrine, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi and Teva; support for attending meetings from AstraZeneca, Chiesi, GSK, Regeneron Pharmaceuticals Inc., Sanofi, Teva and Napp Pharmaceuticals; and other financial or non‐financial interests from AstraZeneca, Boehringer Ingelheim, GSK, Regeneron Pharmaceuticals Inc., Sanofi and Teva. Maarten van den Berge received research grants from Genentech, GSK, Novartis, Roche and Sanofi. Rosa Faner received research grants from AstraZeneca, GSK, Instituto de Salud Carlos III—Spanish National Health Service and Menarini; consulting fees from GSK; and payment or honoraria from Chiesi.

Publisher Copyright:
© 2022 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.

Keywords

COPD
airways
allergy
asthma
bronchitis
chronic obstructive pulmonary disease
emphysema
smoking

Access to Document

10.1111/resp.14325

Cite this

@article{dd57cde02657436cbb599b98f166b2fb,

title = "Treatable traits in the NOVELTY study",

abstract = "Background and objective: Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent and complex diseases that require personalized management. Although a strategy based on treatable traits (TTs) has been proposed, the prevalence and relationship of TTs to the diagnostic label and disease severity established by the attending physician in a real-world setting are unknown. We assessed how the presence/absence of specific TTs relate to the diagnosis and severity of {\textquoteleft}asthma{\textquoteright}, {\textquoteleft}COPD{\textquoteright} or {\textquoteleft}asthma + COPD{\textquoteright}. Methods: The authors selected 30 frequently occurring TTs from the NOVELTY study cohort (NOVEL observational longiTudinal studY; NCT02760329), a large (n = 11,226), global study that systematically collects data in a real-world setting, both in primary care clinics and specialized centres, for patients with {\textquoteleft}asthma{\textquoteright} (n = 5932, 52.8%), {\textquoteleft}COPD{\textquoteright} (n = 3898, 34.7%) or both ({\textquoteleft}asthma + COPD{\textquoteright}; n = 1396, 12.4%). Results: The results indicate that (1) the prevalence of the 30 TTs evaluated varied widely, with a mean ± SD of 4.6 ± 2.6, 5.4 ± 2.6 and 6.4 ± 2.8 TTs/patient in those with {\textquoteleft}asthma{\textquoteright}, {\textquoteleft}COPD{\textquoteright} and {\textquoteleft}asthma + COPD{\textquoteright}, respectively (p < 0.0001); (2) there were no large global geographical variations, but the prevalence of TTs was different in primary versus specialized clinics; (3) several TTs were specific to the diagnosis and severity of disease, but many were not; and (4) both the presence and absence of TTs formed a pattern that is recognized by clinicians to establish a diagnosis and grade its severity. Conclusion: These results provide the largest and most granular characterization of TTs in patients with airway diseases in a real-world setting to date.",

keywords = "COPD, airways, allergy, asthma, bronchitis, chronic obstructive pulmonary disease, emphysema, smoking",

author = "{for the NOVELTY Study Investigators} and Alvar Agust{\'i} and Eleni Rapsomaniki and Richard Beasley and Rod Hughes and Hana M{\"u}llerov{\'a} and Alberto Papi and Pavord, {Ian D.} and {van den Berge}, Maarten and Rosa Faner and Gabriel Benhabib and Ruiz, {Xavier Bocca} and {del Olmo}, Ricardo and Lisanti, {Raul Eduardo} and Gustavo Marino and Walter Mattarucco and Juan Nogueira and Maria Parody and Pablo Pascale and Pablo Rodriguez and Damian Silva and Graciela Svetliza and Victorio, {Carlos F.} and Rolon, {Roxana Willigs} and Anahi Ya{\~n}ez and Gary Anderson and Stuart Baines and Simon Bowler and Peter Bremner and Sheetal Bull and Patrick Carroll and Mariam Chaalan and Claude Farah and Gary Hammerschlag and Kerry Hancock and Zinta Harrington and Gregory Katsoulotos and Joshua Kim and David Langton and Donald Lee and Matthew Peters and Lakshman Prassad and Helen Reddel and Dimitar Sajkov and Francis Santiago and Simpson, {Frederick Graham} and Sze Tai and Paul Thomas and Peter Wark and Can{\c c}ado, {Jos{\'e} Eduardo Delfini} and Cho, {Young Joo}",

note = "Funding Information: The authors thank participants in the NOVELTY study for their willingness to contribute to medical research, and all field investigators for the quality of their work. Editorial support, under the direction of the authors, was provided by Richard Knight, PhD, CMC Connect, McCann Health Medical Communications, and was funded by AstraZeneca, Cambridge, UK, in accordance with Good Publication Practice (GPP3) guidelines. The NOVELTY study is funded by AstraZeneca. Funding Information: Alvar Agust{\'i} has received payments in his role as a member of the scientific committee of NOVELTY; received research grants from AstraZeneca, Chiesi, GSK, Menarini, MSD and Zambon; consulting fees from AstraZeneca, Chiesi, GSK, Menarini, MSD and Zambon; and payment or honoraria from AstraZeneca, Chiesi, GSK, Menarini, MSD and Zambon. Eleni Rapsomaniki and Rod Hughes are employees of AstraZeneca. Hana M{\"u}llerov{\'a} is an employee and shareholder of AstraZeneca. Richard Beasley received research grants from AstraZeneca, Cure Kids (NZ), Genentech, GSK and HRC (NZ); consulting fees from AstraZeneca, Avillion and Theravance; payment or honoraria from AstraZeneca, Cipla and Asthma and Respiratory Foundation NZ; support for attending meetings from AstraZeneca and Theravance; and is the Chair of the adult asthma guidelines group for the Asthma and Respiratory Foundation of NZ. Alberto Papi received research grants from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Pfizer, Sanofi and Teva; consulting fees from AstraZeneca, Avillion, Chiesi, Elpen Pharmaceuticals, GSK, IQVIA, Novartis and Sanofi; and payment or honoraria from AstraZeneca, Avillion, Boehringer Ingelheim, Chiesi, Edmond Pharma, Elpen Pharmaceuticals, GSK, IQVIA, Menarini, MSD, Mundipharma, Novartis, Sanofi, Teva and Zambon. Ian D. Pavord received research grants from Chiesi; consulting fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Dey Pharma, Genentech, GSK, Knopp Biosciences, Merck, MSD, Napp Pharmaceuticals, Novartis, Regeneron Pharmaceuticals Inc., Respivert, Schering‐Plough and Teva; payment or honoraria from Aerocrine, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi and Teva; support for attending meetings from AstraZeneca, Chiesi, GSK, Regeneron Pharmaceuticals Inc., Sanofi, Teva and Napp Pharmaceuticals; and other financial or non‐financial interests from AstraZeneca, Boehringer Ingelheim, GSK, Regeneron Pharmaceuticals Inc., Sanofi and Teva. Maarten van den Berge received research grants from Genentech, GSK, Novartis, Roche and Sanofi. Rosa Faner received research grants from AstraZeneca, GSK, Instituto de Salud Carlos III—Spanish National Health Service and Menarini; consulting fees from GSK; and payment or honoraria from Chiesi. Publisher Copyright: {\textcopyright} 2022 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.",

year = "2022",

month = nov,

doi = "10.1111/resp.14325",

language = "English",

volume = "27",

pages = "929--940",

journal = "Respirology",

issn = "1323-7799",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "11",

}

TY - JOUR

T1 - Treatable traits in the NOVELTY study

AU - for the NOVELTY Study Investigators

AU - Agustí, Alvar

AU - Rapsomaniki, Eleni

AU - Beasley, Richard

AU - Hughes, Rod

AU - Müllerová, Hana

AU - Papi, Alberto

AU - Pavord, Ian D.

AU - van den Berge, Maarten

AU - Faner, Rosa

AU - Benhabib, Gabriel

AU - Ruiz, Xavier Bocca

AU - del Olmo, Ricardo

AU - Lisanti, Raul Eduardo

AU - Marino, Gustavo

AU - Mattarucco, Walter

AU - Nogueira, Juan

AU - Parody, Maria

AU - Pascale, Pablo

AU - Rodriguez, Pablo

AU - Silva, Damian

AU - Svetliza, Graciela

AU - Victorio, Carlos F.

AU - Rolon, Roxana Willigs

AU - Yañez, Anahi

AU - Anderson, Gary

AU - Baines, Stuart

AU - Bowler, Simon

AU - Bremner, Peter

AU - Bull, Sheetal

AU - Carroll, Patrick

AU - Chaalan, Mariam

AU - Farah, Claude

AU - Hammerschlag, Gary

AU - Hancock, Kerry

AU - Harrington, Zinta

AU - Katsoulotos, Gregory

AU - Kim, Joshua

AU - Langton, David

AU - Lee, Donald

AU - Peters, Matthew

AU - Prassad, Lakshman

AU - Reddel, Helen

AU - Sajkov, Dimitar

AU - Santiago, Francis

AU - Simpson, Frederick Graham

AU - Tai, Sze

AU - Thomas, Paul

AU - Wark, Peter

AU - Cançado, José Eduardo Delfini

AU - Cho, Young Joo

N1 - Funding Information: The authors thank participants in the NOVELTY study for their willingness to contribute to medical research, and all field investigators for the quality of their work. Editorial support, under the direction of the authors, was provided by Richard Knight, PhD, CMC Connect, McCann Health Medical Communications, and was funded by AstraZeneca, Cambridge, UK, in accordance with Good Publication Practice (GPP3) guidelines. The NOVELTY study is funded by AstraZeneca. Funding Information: Alvar Agustí has received payments in his role as a member of the scientific committee of NOVELTY; received research grants from AstraZeneca, Chiesi, GSK, Menarini, MSD and Zambon; consulting fees from AstraZeneca, Chiesi, GSK, Menarini, MSD and Zambon; and payment or honoraria from AstraZeneca, Chiesi, GSK, Menarini, MSD and Zambon. Eleni Rapsomaniki and Rod Hughes are employees of AstraZeneca. Hana Müllerová is an employee and shareholder of AstraZeneca. Richard Beasley received research grants from AstraZeneca, Cure Kids (NZ), Genentech, GSK and HRC (NZ); consulting fees from AstraZeneca, Avillion and Theravance; payment or honoraria from AstraZeneca, Cipla and Asthma and Respiratory Foundation NZ; support for attending meetings from AstraZeneca and Theravance; and is the Chair of the adult asthma guidelines group for the Asthma and Respiratory Foundation of NZ. Alberto Papi received research grants from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Pfizer, Sanofi and Teva; consulting fees from AstraZeneca, Avillion, Chiesi, Elpen Pharmaceuticals, GSK, IQVIA, Novartis and Sanofi; and payment or honoraria from AstraZeneca, Avillion, Boehringer Ingelheim, Chiesi, Edmond Pharma, Elpen Pharmaceuticals, GSK, IQVIA, Menarini, MSD, Mundipharma, Novartis, Sanofi, Teva and Zambon. Ian D. Pavord received research grants from Chiesi; consulting fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Dey Pharma, Genentech, GSK, Knopp Biosciences, Merck, MSD, Napp Pharmaceuticals, Novartis, Regeneron Pharmaceuticals Inc., Respivert, Schering‐Plough and Teva; payment or honoraria from Aerocrine, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi and Teva; support for attending meetings from AstraZeneca, Chiesi, GSK, Regeneron Pharmaceuticals Inc., Sanofi, Teva and Napp Pharmaceuticals; and other financial or non‐financial interests from AstraZeneca, Boehringer Ingelheim, GSK, Regeneron Pharmaceuticals Inc., Sanofi and Teva. Maarten van den Berge received research grants from Genentech, GSK, Novartis, Roche and Sanofi. Rosa Faner received research grants from AstraZeneca, GSK, Instituto de Salud Carlos III—Spanish National Health Service and Menarini; consulting fees from GSK; and payment or honoraria from Chiesi. Publisher Copyright: © 2022 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.

PY - 2022/11

Y1 - 2022/11

N2 - Background and objective: Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent and complex diseases that require personalized management. Although a strategy based on treatable traits (TTs) has been proposed, the prevalence and relationship of TTs to the diagnostic label and disease severity established by the attending physician in a real-world setting are unknown. We assessed how the presence/absence of specific TTs relate to the diagnosis and severity of ‘asthma’, ‘COPD’ or ‘asthma + COPD’. Methods: The authors selected 30 frequently occurring TTs from the NOVELTY study cohort (NOVEL observational longiTudinal studY; NCT02760329), a large (n = 11,226), global study that systematically collects data in a real-world setting, both in primary care clinics and specialized centres, for patients with ‘asthma’ (n = 5932, 52.8%), ‘COPD’ (n = 3898, 34.7%) or both (‘asthma + COPD’; n = 1396, 12.4%). Results: The results indicate that (1) the prevalence of the 30 TTs evaluated varied widely, with a mean ± SD of 4.6 ± 2.6, 5.4 ± 2.6 and 6.4 ± 2.8 TTs/patient in those with ‘asthma’, ‘COPD’ and ‘asthma + COPD’, respectively (p < 0.0001); (2) there were no large global geographical variations, but the prevalence of TTs was different in primary versus specialized clinics; (3) several TTs were specific to the diagnosis and severity of disease, but many were not; and (4) both the presence and absence of TTs formed a pattern that is recognized by clinicians to establish a diagnosis and grade its severity. Conclusion: These results provide the largest and most granular characterization of TTs in patients with airway diseases in a real-world setting to date.

AB - Background and objective: Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent and complex diseases that require personalized management. Although a strategy based on treatable traits (TTs) has been proposed, the prevalence and relationship of TTs to the diagnostic label and disease severity established by the attending physician in a real-world setting are unknown. We assessed how the presence/absence of specific TTs relate to the diagnosis and severity of ‘asthma’, ‘COPD’ or ‘asthma + COPD’. Methods: The authors selected 30 frequently occurring TTs from the NOVELTY study cohort (NOVEL observational longiTudinal studY; NCT02760329), a large (n = 11,226), global study that systematically collects data in a real-world setting, both in primary care clinics and specialized centres, for patients with ‘asthma’ (n = 5932, 52.8%), ‘COPD’ (n = 3898, 34.7%) or both (‘asthma + COPD’; n = 1396, 12.4%). Results: The results indicate that (1) the prevalence of the 30 TTs evaluated varied widely, with a mean ± SD of 4.6 ± 2.6, 5.4 ± 2.6 and 6.4 ± 2.8 TTs/patient in those with ‘asthma’, ‘COPD’ and ‘asthma + COPD’, respectively (p < 0.0001); (2) there were no large global geographical variations, but the prevalence of TTs was different in primary versus specialized clinics; (3) several TTs were specific to the diagnosis and severity of disease, but many were not; and (4) both the presence and absence of TTs formed a pattern that is recognized by clinicians to establish a diagnosis and grade its severity. Conclusion: These results provide the largest and most granular characterization of TTs in patients with airway diseases in a real-world setting to date.

KW - COPD

KW - airways

KW - allergy

KW - asthma

KW - bronchitis

KW - chronic obstructive pulmonary disease

KW - emphysema

KW - smoking

UR - http://www.scopus.com/inward/record.url?scp=85134514840&partnerID=8YFLogxK

U2 - 10.1111/resp.14325

DO - 10.1111/resp.14325

M3 - Article

C2 - 35861464

AN - SCOPUS:85134514840

SN - 1323-7799

VL - 27

SP - 929

EP - 940

JO - Respirology

JF - Respirology

IS - 11

ER -

Treatable traits in the NOVELTY study

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this